-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IC9 CAR.19 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IC9 CAR.19...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IC9 CAR.19 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IC9 CAR.19 in B-Cell...
-
Innovation Ranking
Innovation Ranking – Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products...
-
Product Insights
Graft Versus Host Disease (GVHD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Graft Versus Host Disease (GVHD) Clinical Trial Market Report Overview Graft versus host disease (GVHD) clinical trial market research report provides top line data relating to the clinical trials on Graft Versus Host Disease (GVHD). The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-411 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-411 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-411 in Small-Cell Lung Cancer Drug Details: SC-1 (BNT-411) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy For GD2 Expressing Solid Tumors in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy For GD2 Expressing Solid Tumors in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy For GD2 Expressing Solid Tumors...
-
Product Insights
NewSickle Cell Disease – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease – Drugs In Development, 2024 report and make more profitable business decisions. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewNodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Nodal marginal zone B-cell lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma that affects the lymph nodes. It is a slow-growing cancer that can sometimes become aggressive. NMZL is more common in older adults, but it can occur in younger people as well. The exact cause of NMZL is unknown, but some genetic factors may be involved. NMZL...
-
Product Insights
NewSplenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Splenic marginal zone lymphoma (SMZL) is a rare type of B-cell lymphoma that affects the spleen, bone marrow, and sometimes the blood. It is a low-grade neoplasm that originates from the germinal centers of the splenic white pulp. The neoplastic cells are small lymphocytes and larger transformed lymphoblasts that invade the mantle and marginal zones of the spleen and...